Hongqi Pharmaceutical
HONGQI PHARMACEUTICAL
Cherish life, pay attention to health.
CHERISH LIFE CARE ABOUT HEALTH
The initiation meeting of the pilot project on the feasibility of promoting the use of anti-tuberculosis fixed-dose compound preparations in tuberculosis hospitals was successfully held in Chengdu
Category:
Company News
Author:
Source:
Add time:2021-04-17 10:10
On April 11, 2021, the anti-tuberculosis fixed-dose compound preparation (hereinafter referred to as “FDC”), sponsored by the China National Tuberculosis Association and co-organized by Fosun Pharma’s member company Shenyang Hongqi Pharmaceutical Co., Ltd., was promoted and used in tuberculosis specialist hospitals. The feasibility pilot project launch meeting was successfully held in Chengdu. Cheng Shiming, Secretary-General and Vice-Chairman of the Chinese Antituberculosis Association, Zhong Qiu, Vice-Chairman, and Fan Haiying, Deputy Secretary-General; Chen Mingting, Deputy Director of the Tuberculosis Prevention and Control Center of China CDC, Director Zhou Lin, Chief Physician and Deputy Director Liu Eryong, Deputy Director of the Chinese Center for Disease Control and Prevention Researcher and researcher Wang Ni participated in the kick-off meeting. Also participating in the kick-off meeting were Zhang Zhongfa, director of Shandong Provincial Public Health Clinical Center, Zhang Linglin, deputy director of Sichuan Center for Disease Control and Prevention, Chen Chuang, director of Sichuan Center for Disease Control and Prevention, and Jiangxi Province Zheng Jiangang, director of the Center for Disease Control and Prevention, Bai Liqiong, deputy director of Hunan Tuberculosis Prevention and Control Institute, Zhu Limei, deputy director of the Jiangsu Center for Disease Control and Prevention; Zhang Xia, deputy director of Nanjing Second Hospital from eight designated tuberculosis hospitals in four provinces , Vice President Jiang Liangshuang of Chengdu Public Health Center and project leaders of designated hospitals; General Manager Yang Bo, Deputy General Manager Lv Wenhua and heads of various departments of Shenyang Hongqi Pharmaceutical; Wang Xiaogang, Vice President of Beijing Fuller Cloud Data Technology Co., Ltd. and related persons in charge A total of more than 60 people attended the kick-off meeting.
Executive director of China National Tuberculosis Association and General Manager of Shenyang Hongqi Pharmaceutical Yang Bo, on behalf of the company, expressed sincere gratitude to the leaders and experts who participated in the kick-off meeting. Fosun Pharma has been committed to China's public health prevention and treatment, and we will continue to do so Support the work of the China National Tuberculosis Association.
After the opening ceremony, researcher Wang Ni gave a detailed introduction to the project background, purpose, main activities, case inclusion, treatment management, on-site evaluation and quality control.
Director Zhou Lin conducted an in-depth interpretation of FDC's prescription, usage and dosage, and treatment of adverse reactions. Director Zhou Lin pointed out that although fixed-dose combination agents have been used in my country for decades, some clinicians still have some misunderstandings about them. Hongqi Pharmaceutical’s quadruple FDC can meet the daily consumption of 50-70kg, 80 kg per day. %-85% of the body weight range of tuberculosis patients. At the same time, various national-level researches have shown that there is no significant difference between FDC and powder medicine in the treatment effect and the incidence of adverse reactions, and it can reduce the incidence of serious adverse reactions and improve patient compliance. It is worthwhile Clinical promotion and use.
Director Zhang Jing of the China Medical and Health Development Foundation and Zhang Yongwang, Manager of Beijing Fuller Cloud Data Technology Co., Ltd. respectively introduced the China Medical Development Foundation and the electronic pill box tuberculosis prevention and control information platform.
Experts from Jiangxi, Shandong, Jiangsu, and Sichuan introduced the basic situation of the province and the use of FDC in designated hospitals, and finally discussed the relevant content of this meeting. Director Zhou Lin answered each expert’s questions one by one. . Mr. Zhong Qiu, vice chairman of the Chinese Antituberculosis Association, summarized this session. The vice chairman of Zhong Qiu explained the recognition of FDC from the perspective of doctors based on his own experience of clinicians.
Finally, the Secretary-General Cheng Shiming of the China National Tuberculosis Association summarized the meeting: The kick-off meeting was very successful. Thank you all experts for attending the meeting and paying attention to this project. I believe that all the experts have their strong support The project will surely be carried out smoothly and completed with high quality to provide data support for the prevention and control of tuberculosis in the 14th Five-Year Plan.
